Indicated for low-risk patients with upper gastrointestinal bleeding (caused by peptic ulcer, acute stress ulcer, hemorrhagic gastritis, etc.). Fokam Pharmaceutical's roxatidine hydrochloride acetate has a CDE registration status of "I".